KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma.
作者信息
Pandey Abhishek
机构信息
Department of Urology, AIIMS, Bhubaneswar, Odisha, India.
出版信息
Indian J Urol. 2022 Jan-Mar;38(1):75-76. doi: 10.4103/iju.iju_365_21. Epub 2022 Jan 1.
Abstract
摘要
相似文献
1
KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma.KEYNOTE-564：肾细胞癌的辅助免疫治疗。
Indian J Urol. 2022 Jan-Mar;38(1):75-76. doi: 10.4103/iju.iju_365_21. Epub 2022 Jan 1.
2
A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.根据预期的癌症特异性死亡率，优化当前高风险非转移性肾细胞癌辅助免疫治疗试验中的选择的呼吁。
Clin Genitourin Cancer. 2020 Aug;18(4):314-321.e1. doi: 10.1016/j.clgc.2019.11.010. Epub 2019 Dec 5.
3
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.当代适合辅助检查点抑制剂试验的肾细胞癌患者的患病率、无疾病生存率和总生存率。
Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7.
4
Adjuvant therapy in renal cell carcinoma.肾细胞癌的辅助治疗。
Cancer Treat Rev. 2017 Nov;60:152-157. doi: 10.1016/j.ctrv.2017.09.004. Epub 2017 Sep 23.
5
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.新辅助和辅助免疫治疗在肾细胞癌中的应用。
World J Urol. 2021 May;39(5):1369-1376. doi: 10.1007/s00345-020-03550-z. Epub 2021 Jan 1.
6
Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.局限性高危肾细胞癌的辅助治疗。
Urol Clin North Am. 2020 Aug;47(3):345-358. doi: 10.1016/j.ucl.2020.04.007.
7
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?辅助免疫疗法在肾细胞癌中的益处：神话还是现实？
PLoS One. 2017 Feb 27;12(2):e0172341. doi: 10.1371/journal.pone.0172341. eCollection 2017.
8
The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.根治性肾切除术后辅助免疫治疗的作用及pT3N0M0肾细胞癌的预后因素
Anticancer Res. 1999 Nov-Dec;19(6C):5593-7.
9
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.派姆单抗联合阿昔替尼对比舒尼替尼作为晚期肾细胞癌的一线治疗（KEYNOTE-426）：一项随机、开放标签、III 期试验的延长随访。
Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.
10
May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.辅助治疗在肾细胞癌管理中能发挥作用吗？文献综述与正在进行的试验
Anticancer Agents Med Chem. 2017;17(12):1633-1643. doi: 10.2174/1871520617666170213114512.
引用本文的文献
1
Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.PD-1 抑制剂治疗转移性肾细胞癌引起的类肉瘤样反应和甲状腺功能减退症：病例报告及文献复习。
BMC Pulm Med. 2024 Mar 8;24(1):123. doi: 10.1186/s12890-024-02943-9.
2
Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report.帕博利珠单抗诱导的透明细胞肾细胞癌患者横纹肌溶解症：一例报告
Case Rep Oncol. 2023 Aug 25;16(1):728-733. doi: 10.1159/000532100. eCollection 2023 Jan-Dec.
3
Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.免疫调节与预后指示：新型多基因标志物在透明细胞肾细胞癌中的作用。
BMC Cancer. 2023 Jul 12;23(1):649. doi: 10.1186/s12885-023-11150-4.
本文引用的文献
1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.肾细胞癌肾切除术后辅助帕博利珠单抗。
N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.
2
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
3
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
4
Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.辅助酪氨酸激酶抑制剂治疗肾细胞癌：可用临床试验的荟萃分析。
Clin Genitourin Cancer. 2019 Apr;17(2):e339-e344. doi: 10.1016/j.clgc.2018.12.011. Epub 2019 Jan 4.
Zotero 插件